Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More
Learn More
HLA A Antibody (CATA-1), PE/Atto594, Novus Biologicals™

Mouse Monoclonal Antibody
Supplier: Novus Biologicals NBP247673PEATT594
Description
HLA A Monoclonal specifically detects HLA A in Human samples. It is validated for Flow Cytometry.Specifications
HLA A | |
Monoclonal | |
PE/ATTO 594 | |
PBS with 0.05% Sodium Azide | |
HLA-A | |
Normal human peripheral blood lymphocytes of phenotype A1, Aw32, B7, B37, Cw-, Cw-, DR2, DRw10 | |
0.1 mL | |
Primary | |
This monoclonal antibody reacts with cells bearing HLA-A25 or HLA-Aw32 antigens. In addition, a reaction was observed with a cell of phenotype A2, Aw31; B17, Bw49. HLA-A, with HLA-B and HLA-C, belongs to major histocompatibility complex (MHC) class I antigens and expresses constitutively on all nucleated cells. HLA system comprises closely linked genes controlling highly polymorphic proteins involved in the presentation of peptides to the T-cell receptor, inhibition of NK cell cytotoxicity, and rejection of tissue allotransplantation. Specific alleles at HLA loci are associated with diseases. This monoclonal antibody is specifically applicable for typing peripheral T cells for the antigens HLA-A25 and HLA-Aw32. | |
Store at 4°C in the dark. Do not freeze. |
Flow Cytometry | |
CATA-1 | |
Flow Cytometry | |
A-10 alpha chain, FLJ26655, HLA class I histocompatibility antigen, A-1 alpha chain, HLA class I histocompatibility antigen, A-28 alpha chain, HLA class I histocompatibility antigen, A-9 alpha chain, HLAA, major histocompatibility complex, class I, A, MHC class I antigen A*1, MHC class I antigen A*11, MHC class I antigen A*80 | |
Mouse | |
Protein A or G purified | |
Adaptive Immunity, Cell Biology, Immunology | |
3105.0 | |
Human | |
IgG2a κ |
Product Content Correction
Your input is important to us. Please complete this form to provide feedback related to the content on this product.
Product Title
Spot an opportunity for improvement?Share a Content Correction